First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively
Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials & business updates
SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported consolidated first quarter 2021 financial results.
2021 First Quarter Company Financial Results:
|
Three Months Ended | |||||||||||||||
Financial Highlights (in thousands)
|
March 31, | |||||||||||||||
Gross product sales
|
2021 | 2020 | $ change | % change | ||||||||||||
Mytesi
|
$ | 4,558 | $ | 1,304 | $ | 3,254 | 250 | % | ||||||||
Neonorm
|
33 | 34 | (1 | ) | -3 | % | ||||||||||
Total gross product sales
|
4,591 | 1,338 | 3,253 | 243 | % | |||||||||||
Medicare rebates
|
(1,097 | ) | (68 | ) | (1,029 | ) | 1513 | % | ||||||||
Sales discounts
|
(1,732 | ) | (261 | ) | (1,471 | ) | 564 | % | ||||||||
Sales returns
|
(20 | ) | (18 | ) | (2 | ) | 11 | % | ||||||||
Wholesaler fee
|
(501 | ) | (122 | ) | (379 | ) | 311 | % | ||||||||
Net product sales
|
$ | 1,241 | $ | 869 | $ | 372 | 43 | % | ||||||||
|
|
Three Months Ended | |||||||||||||||
Financial Highlights
|
March 31, | |||||||||||||||
(in thousands, except per share amounts)
|
2021 | 2020 | $ change | % change | ||||||||||||
Net product revenue
|
$ | 1,241 | $ | 869 | 372 | 43 | % | |||||||||
Loss from operations
|
$ | (8,766 | ) | $ | (7,654 | ) | (1,112 | ) | 15 | % | ||||||
Net loss
|
$ | (12,009 | ) | $ | (7,936 | ) | (4,073 | ) | 51 | % | ||||||
Net loss per share, basic and diluted
|
$ | (0.10 | ) | $ | (0.56 | ) | 0.46 | -82 | % |
|
Month Ending | |||||||
|
March 31, | |||||||
(in thousands)
|
2021 | 2020 | ||||||
|
(unaudited) | |||||||
Net loss
|
$ | (12,009 | ) | (7,936 | ) | |||
Adjustments:
|
||||||||
Interest expense
|
1,901 | 199 | ||||||
Property and equipment depreciation
|
9 | 10 | ||||||
Amortization of intangible assets
|
422 | 422 | ||||||
Share-based compensation expense
|
634 | 760 | ||||||
Income taxes
|
– | – | ||||||
Non-GAAP EBITDA
|
(9,043 | ) | (6,545 | ) | ||||
Impairment of indefinite-lived intangible assets
|
– | |||||||
Loss on extinguishment of debt
|
753 | – | ||||||
Series 3 warrants inducement expense
|
1,462 | – | ||||||
Series B convertible preferred stock inducement expense
|
– | 1,647 | ||||||
Non-GAAP Recurring EBITDA
|
$ | (6,828 | ) | $ | (4,898 | ) |
Note Regarding Use of Non-GAAP Measures
The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA, and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflets the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.
Gross sales percentages issued by the Company are based on gross sales figures that represent Mytesi orders placed by wholesalers with Jaguar’s third-party logistics warehouse, less allowances for rebates, chargebacks, and discounts, which generate the cash flows for Napo. Gross sales are used internally by management as an indicator of and to monitor operating performance, including sales performance of Mytesi, salesperson performance, and product growth or declines. The Company believes that the presentation of gross sales provides a closer to real-time useful measure of our operating performance. Gross sales are not a measure that is recognized under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to net sales, which is determined in accordance with GAAP, and should not be used alone as an indicator of operating performance in place of net sales. Additionally, gross sales may not be comparable to similarly titled measures used by other companies, as gross sales have been defined by the Company’s internal reporting practices. In addition, gross sales may not be realized in the form of cash receipts as promotional payments and allowances may be deducted from payments received from certain customers. Mytesi gross sales are reduced by Medicare, ADAP 340B chargebacks, returns, and wholesale distribution fees based on historical trends to determine net sales.
The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar’s performance and provide useful information to investors regarding the Company’s results of operations and financial condition.
Participation Instructions for Webcast
When: Monday, May 17, 2021, at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Dial-in (US Toll Free): 844-512-2921
Dial-in (International): 412-317-6671
Replay Pin Number: 5530970
Replay of the webcast on the investor relations section of Jaguar’s website (click here)
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the expectation that Jaguar will host an investor webcast on May 17, 2021. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/647662/Jaguar-Health-Inc-Reports-2021-First-Quarter-Financial-Results
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Piper…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Piper…
Amid technologist shortage, new mammography innovation was designed through intensive collaboration with technologists will help…
Irvine Labs' FDA-compliant and DEA-registered facility enables psilocybin production and psilocybin exports and imports to…
Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will…
Princeton Health Magazine features Dr. Yamasaki on modern approaches to treating Bell's Palsy. PRINCETON, NEW…